{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:09:29Z","timestamp":1788318569442,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jinf.2019.10.007","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:51:07Z","timestamp":1571255467000},"page":"503-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group"],"prefix":"10.1016","volume":"79","author":[{"given":"Daniel","family":"Bradshaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L","family":"Mbisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Geretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan J","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham S","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McLauchlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mutimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jinf.2019.10.007_bib0002","first-page":"1477","article-title":"HCV guidance: recommendations for testing, managing, and treating hepatitis C","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2019.10.007_bib0003","unstructured":"Global health sector strategy on viral hepatitis, 2016\u20132021: towards ending viral hepatitis 2016 [Available from:http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf?sequence=1."},{"issue":"5386","key":"10.1016\/j.jinf.2019.10.007_bib0004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jinf.2019.10.007_bib0005","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/JVI.00201-09","article-title":"Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo","volume":"83","author":"Cuevas","year":"2009","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.jinf.2019.10.007_bib0006","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jinf.2019.10.007_bib0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in Hcv NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jinf.2019.10.007_bib0008","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0009","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep4.1060","article-title":"The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment","volume":"1","author":"Gane","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jinf.2019.10.007_bib0010","series-title":"Prevalence of NS3 and NS5A resistance associated substitutions through European DAA-failures","author":"Popping","year":"2018"},{"issue":"3","key":"10.1016\/j.jinf.2019.10.007_bib0011","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2019.10.007_bib0012","article-title":"Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated variants (RAVs) after treatment with grazoprevir-containing regimens in patients with chronic hepatitis C virus (HCV) infection","year":"2016"},{"issue":"1","key":"10.1016\/j.jinf.2019.10.007_bib0013","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12859-018-2459-9","article-title":"GLUE: a flexible software system for virus sequence data","volume":"19","author":"Singer","year":"2018","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.jinf.2019.10.007_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"issue":"3","key":"10.1016\/j.jinf.2019.10.007_bib0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","article-title":"Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir","volume":"152","author":"Komatsu","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jinf.2019.10.007_bib0016","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1\u20136 HCV infection treated with sofosbuvir\/velpatasvir in the phase 3 studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jinf.2019.10.007_bib0017","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2019.10.007_bib0018","unstructured":"Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., et al. International committee on taxonomy of viruses (ICTV). HCV Classification2017[Available from: Available at:https:\/\/talk.ictvonline.org\/ictv_wikis\/flaviviridae\/w\/sg_flavi\/56\/hcv-classification."},{"issue":"10","key":"10.1016\/j.jinf.2019.10.007_bib0019","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1128\/JCM.00330-16","article-title":"Comparison of next-generation sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes","volume":"54","author":"Thomson","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.jinf.2019.10.007_bib0020","doi-asserted-by":"crossref","first-page":"e8209","DOI":"10.1371\/journal.pone.0008209","article-title":"Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice","volume":"4","author":"Chevaliez","year":"2009","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0021","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jhep.2017.06.035","article-title":"Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries","volume":"67","author":"da Silva Filipe","year":"2017","journal-title":"J Hepatol"},{"issue":"Pt 8","key":"10.1016\/j.jinf.2019.10.007_bib0022","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1099\/vir.0.048835-0","article-title":"Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1","volume":"94","author":"Li","year":"2013","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir\u2013sofosbuvir (SHARED): a single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jvh.12795","article-title":"Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4","volume":"25","author":"Camus","year":"2018","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0026","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","article-title":"Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r","volume":"69","author":"Fourati","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0027","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jmv.23215","article-title":"Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa","volume":"84","author":"Gededzha","year":"2012","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179064","article-title":"Genetic diversity of hepatitis C virus in Ethiopia","volume":"12","author":"Hundie","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jinf.2019.10.007_bib0029","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apt.15100","article-title":"Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection","volume":"49","author":"Mettikanont","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0030","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.30342","article-title":"Highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments","volume":"69","author":"Davis","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0031","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2017.05.027","article-title":"Origin, prevalence and response to therapy of hepatitis C virus genotype 2k\/1b chimeras","volume":"67","author":"Susser","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2019.10.007_bib0032","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/5584_2018_190","article-title":"Next-generation sequencing of hepatitis C virus (HCV) mixed-genotype infections in anti-HCV-negative blood donors","volume":"1096","author":"Janiak","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0033","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrgastro.2015.36","article-title":"Mixed HCV infection and reinfection in people who inject drugs \u2013 impact on therapy","volume":"12","author":"Cunningham","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jinf.2019.10.007_bib0034","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.27192","article-title":"Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment","volume":"61","author":"Abdelrahman","year":"2015","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1016\/j.jinf.2019.10.007_bib0035","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0036","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","article-title":"HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe","volume":"66","author":"Ingiliz","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0037","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0038","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/thoraxjnl-2016-209579","article-title":"High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population","volume":"73","author":"Aldridge","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2019.10.007_bib0039","unstructured":"Public Health England. Hepatitis C in England: 2018 report 2018 [Available from:https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/693917\/HCV_in_England_2018.pdf."},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir\u2013sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2019.10.007_bib0041","series-title":"Real-world effectiveness of directly-acting antiviral treatments in England: data on all treated patients from the national registry","author":"Drysdale","year":"2018"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0042","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0043","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection","volume":"149","author":"Gane","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0044","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(15)00529-0","article-title":"Ledipasvir\u2013sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study","volume":"16","author":"Abergel","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2019.10.007_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/apt.15043","article-title":"Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir","volume":"49","author":"Nguyen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jinf.2019.10.007_bib0046","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1\u20137 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.jinf.2019.10.007_bib0047","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jinf.2019.10.007_bib0048","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1128\/AAC.00051-16","article-title":"The combination of grazoprevir, a hepatitis C virus (HCV) NS3\/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons","volume":"60","author":"Lahser","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0049","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/hep.29693","article-title":"Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives","volume":"67","author":"Harrington","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2019.10.007_bib0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jvh.13037","article-title":"The accuracy of baseline viral load for predicting the efficacy of elbasvir\/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis","volume":"26","author":"Serfaty","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jinf.2019.10.007_bib0051","article-title":"GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier European association for the study of the liver","year":"2013"},{"issue":"8","key":"10.1016\/j.jinf.2019.10.007_bib0052","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jvh.13116","article-title":"In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6","volume":"26","author":"Dvory-Sobol","year":"2019","journal-title":"J Viral Hepat"},{"issue":"27","key":"10.1016\/j.jinf.2019.10.007_bib0053","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2019.10.007_bib0054","series-title":"Sofosbuvir\/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: an integrated analysis of phase 2 and phase 3 clinical trials","author":"Roberts","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0055","article-title":"Safety and efficacy of sofosbuvir\/velpatasvir with and without ribavirin in genotype 3 HCV-infected patients with cirrhosis","year":"2018"},{"issue":"9","key":"10.1016\/j.jinf.2019.10.007_bib0056","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"von Felden","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"27","key":"10.1016\/j.jinf.2019.10.007_bib0057","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2019.10.007_bib0058","series-title":"The presence of resistance-associated substitutions (A30K+L31M) in DAA treatment-Na\u00efve patients with genotype-3b HCV infection","author":"Kong","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0059","unstructured":"Antiviral resistance testing in the management of hepatitis C virus infection: Public Health England; 2018[Available from:https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/762347\/Antiviral_resistance_testing_in_the_management_of_hepatitis_C_virus_infection.pdf."},{"key":"10.1016\/j.jinf.2019.10.007_bib0060","unstructured":"AbbVie. Summary of product characteristics: maviret 100\u00a0mg\/40\u00a0mg film coated tablets 2019 [updated 02\/09\/2019. Available from:https:\/\/www.medicines.org.uk\/emc\/product\/763\/smpc."},{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0061","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0062","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/pibrentasvir in patients with HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0063","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2019.10.007_bib0064","series-title":"Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies","article-title":"Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies","year":"2016"},{"key":"10.1016\/j.jinf.2019.10.007_bib0065","series-title":"Sofosbuvir\/velpatasvir\/voxilaprevir in DAA failure patients with cirrhosis","author":"Hezode","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0066","series-title":"Retreatment with SOF\/VEL\/VOX in treatment-experienced patients with and without HIV: the RESOLVE study","author":"Covert","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0067","series-title":"Sofosbuvir\/velpatasvir\/voxilaprevir (SOF\/VEL\/VOX) in care of chronic hepatitis C patients; clinical practice experience from the trio network","author":"Bacon","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0068","series-title":"Real-world impact of resistance-associated substitutions on re-treatment after ledipasvir\/sofosbuvir virologic failure in hepatitis C patients","author":"Backus","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0069","series-title":"Real-world safety and effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir and glecaprevir\/pibrentasvir in hepatitis C infected patients","first-page":"705","author":"Saxena","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0070","series-title":"Resistance analysis in direct acting antiviral-experienced patients with chronic hepatitis C virus infection treated with sofosbuvir\/velpatasvir\/voxilaprevir (SOF\/VEL\/VOX) \u2013 results from the Frankfurt resistance database","author":"Vermehren","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0071","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jinf.2019.10.007_bib0072","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients","volume":"26","author":"Belperio","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jinf.2019.10.007_bib0073","series-title":"Retreatment with voxilaprevir\/velpatasvir\/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure \u2013 results from the German Hepatitis C-Registry (DHC-R)","author":"Vermehren","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0074","doi-asserted-by":"crossref","unstructured":"Degasperi E., Spinetti A., Lombardi A., Landonio S., Rossi M.C., Pasulo L., et al. Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol 2019 pii: S0168-8278.","DOI":"10.1016\/j.jhep.2019.07.020"},{"key":"10.1016\/j.jinf.2019.10.007_bib0075","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","article-title":"Sofosbuvir\/Velpatasvir\/Voxilaprevir for previous treatment failures with glecaprevir\/pibrentasvir in chronic hepatitis C infection","volume":"114","author":"Pearlman","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0076","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2019.10.007_bib0077","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.08.008","article-title":"Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy","author":"Lok","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jinf.2019.10.007_bib0078","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00535-018-01543-9","article-title":"NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir","volume":"54","author":"Uemura","year":"2019","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jinf.2019.10.007_bib0079","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-018-1520-9","article-title":"Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures","volume":"54","author":"Osawa","year":"2019","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jinf.2019.10.007_bib0080","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"Sofosbuvir\u2013velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen","volume":"66","author":"Gane","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2019.10.007_bib0081","series-title":"Sofosbuvir\/velpatasvir \u00b1 ribavirin for retreatment of patients with chronic hepatitis C virus (HCV) infection failing to a previous DAA combination regimen","author":"Brancaccio","year":"2018"},{"key":"10.1016\/j.jinf.2019.10.007_bib0082","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14201","article-title":"Retreatment with elbasvir, grazoprevir, sofosbuvir +\/\u2212 ribavirin is effective for GT3 and GT1\/4\/6 HCV infection after relapse","author":"Papaluca","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jinf.2019.10.007_bib0083","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: a randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jinf.2019.10.007_bib0084","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cix916","article-title":"Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 revenge study","volume":"66","author":"de Ledinghen","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2019.10.007_bib0085","series-title":"Retreatment of hepatitis C virus infection in patients who failed glecaprevir\/pibrentasvir","article-title":"Retreatment of hepatitis C virus infection in patients who failed glecaprevir\/pibrentasvir","year":"2018"},{"issue":"6","key":"10.1016\/j.jinf.2019.10.007_bib0086","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445319303172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445319303172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:27:42Z","timestamp":1759008462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445319303172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0163445319303172"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2019.10.007","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2019.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd on behalf of The British Infection Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}